ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) saw a significant drop in short interest in January. As of January 31st, there was short interest totalling 16,230,000 shares, a drop of 5.2 ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ACAD's Other Pipeline Goals for 2025-2026 In a separate press release, the company announced that it expects to generate more than $1 billion in combined net sales for Nuplazid and Daybue in 2025.

Morgan Stanley analyst Jeffrey Hung maintained a Hold rating on ACADIA Pharmaceuticals (ACAD – Research Report) today and set a price target of ...

Deutsche Bank initiated coverage of Acadia Pharmaceuticals (ACAD) with a Hold rating and $22 price target Maximize Your Portfolio with Data ...

W W King and Newberry Acad will take the court on Tuesday, Feb. 4 at 6:30 p.m. ET. Don't miss out on any of the action with ...